Preoperative CA-125 level as a predictor of non optimal cytoreduction of advanced epithelial ovarian cancer

被引:32
|
作者
Gemer, O [1 ]
Segal, S [1 ]
Kopmar, A [1 ]
机构
[1] Ben Gurion Univ Negev, Fac Hlth Sci, Barzilai Med Ctr, Dept Obstet & Gynecol, IL-78306 Ashkelon, Israel
关键词
CA; 125; cytoreduction; ovarian cancer;
D O I
10.1034/j.1600-0412.2001.080006583.x
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background. Suboptimal cytoreduction of advanced ovarian cancer is related to initial tumor bulk which correlates with CA125 level. Methods. Retrospective record study of 40 patients with stage III ovarian cancer. The ability of a CA125 threshold level of 500 U/mL to predict suboptimal cytoreduction was determined. Results. Twenty-four (60%) of the patients were optimally cytoreduced. At the CA125 cut off level of 500 U/mL the sensitivity for predicting suboptimal debulking was 62% and specificity was 83%. Above a CA 125 level of 1500 U/mL none of the patients were optimally cytoreduced. Conclusions. More data are needed to determine the CA125 cut off level at which the standard approach of initial laparotomy and cytoreduction may be modified.
引用
收藏
页码:583 / 585
页数:3
相关论文
共 50 条
  • [41] Limitations to the use of the CA-125 antigen level in ovarian cancer
    Maurie Markman
    Current Oncology Reports, 2003, 5 (4) : 263 - 264
  • [42] Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer
    Kim, Hee Seung
    Park, Noh Hyun
    Chung, Hyun Hoon
    Kim, Jae Weon
    Song, Yong Sang
    Kang, Soon Beom
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2008, 87 (11) : 1136 - 1142
  • [43] CA-125 Level as a Prognostic Indicator in Type I and Type II Epithelial Ovarian Cancer
    Chen, Xiaoxiang
    Zhang, Jing
    Cheng, Wenjun
    Chang, Doo Young
    Huang, Jianfei
    Wang, Xuan
    Jia, Lizhou
    Rosen, Daniel G.
    Zhang, Wei
    Yang, Da
    Gershenson, David M.
    Sood, Anil K.
    Bast, Robert C., Jr.
    Liu, Jinsong
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (05) : 815 - 822
  • [44] Comparative Study Between Serum Level of Lysophosphatidic Acid and CA-125 in Epithelial Ovarian Cancer
    Rady H.A.
    Othman M.M.
    Agamia A.F.M.
    Mahmoud M.H.
    Elghrabawy S.A.
    Indian Journal of Gynecologic Oncology, 2018, 16 (3)
  • [45] Continuing neoadjuvant chemotherapy until CA-125 reaches the nadir improves complete cytoreduction by interval debulking surgery in patients with advanced epithelial ovarian cancer
    Nakamura, K.
    Kitahara, Y.
    Ibuki, Y.
    Kogure, K.
    Kigure, K.
    Hirakawa, T.
    Kanuma, T.
    GYNECOLOGIC ONCOLOGY, 2017, 145 : 99 - 99
  • [46] Prognostic Significance of CA-125 in the Management of Patients with Recurrent Epithelial Ovarian Carcinoma Selected for Secondary Cytoreduction
    Mahner, Sven
    Woelber, Linn
    Jung, Sabine
    Eulenburg, Christine Zu
    Ihnen, Maike
    Schwarz, Joerg
    Sehouli, Jalid
    Jaenicke, Fritz
    ANTICANCER RESEARCH, 2009, 29 (07) : 2817 - 2821
  • [47] CA-125 AS A TUMOR-MARKER IN EPITHELIAL OVARIAN-CANCER
    SHEEHAN, JD
    DUFFY, MJ
    ALLEN, MA
    FENNELLY, JJ
    IRISH JOURNAL OF MEDICAL SCIENCE, 1989, 158 (01) : 10 - 13
  • [48] CA-125 IN OVARIAN-CANCER
    VANDERBURG, MEL
    LAMMES, FB
    VERWEIJ, J
    NETHERLANDS JOURNAL OF MEDICINE, 1992, 40 (1-2): : 36 - 51
  • [49] Preoperative CA-125 levels in patients with hereditary compared to sporadic epithelial ovarian carcinoma
    Leitao, M
    Boyd, J
    GYNECOLOGIC ONCOLOGY, 2002, 84 (03) : 413 - 415
  • [50] THE ROLE OF CANCER ANTIGEN-125 (CA-125) IN THE MANAGEMENT OF OVARIAN EPITHELIAL CARCINOMAS
    ALTARAS, MM
    GOLDBERG, GL
    LEVIN, W
    RADIO, FF
    BLOCH, B
    DARGE, L
    SMITH, JA
    GYNECOLOGIC ONCOLOGY, 1988, 30 (01) : 26 - 34